PROTEOMICS: Plexxikon Looks to Beat Syrrx, Pharma | GenomeWeb

Don’t tell Plexxikon there’s no money left in investors’ pockets. The Berkeley, Calif.-based company recently closed a $27 million funding round led by Walden International.

Founded in 1999 by a team of scientists with expertise in cell signaling proteins and their potential as drug targets, Plexxikon differentiates itself from structural proteomics competitors such as Syrrx, Structural Genomix, and big pharma companies by not pursuing a high-throughput crystallography approach.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

In Nature this week: genetic history of HIV in the US, and more.